Cancer & OncologyOral SERDs for breast cancer: how they differ from older endocrine therapy
Oral SERDs degrade the estrogen receptor and are changing treatment for ESR1-mutated breast cancer. Here is how they differ from aromatase inhibitors, tamoxifen, and fulvestrant.
Read the Full Bite →